Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Hypofractionated Whole-Pelvis Proton Therapy With HDR Boost

NCT06591819 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT06591819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06591819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Hypofractionated Whole-Pelvis Proton Therapy With HDR Boost
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
January 15, 2025
Completion date
December 31, 2035
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer